EA201600014A1 - Комбинация производного имидазопиридазина и митотического средства для лечения рака - Google Patents

Комбинация производного имидазопиридазина и митотического средства для лечения рака

Info

Publication number
EA201600014A1
EA201600014A1 EA201600014A EA201600014A EA201600014A1 EA 201600014 A1 EA201600014 A1 EA 201600014A1 EA 201600014 A EA201600014 A EA 201600014A EA 201600014 A EA201600014 A EA 201600014A EA 201600014 A1 EA201600014 A1 EA 201600014A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
combination
treatment
mitotic
imidazopiridazin
Prior art date
Application number
EA201600014A
Other languages
English (en)
Other versions
EA028800B1 (ru
Inventor
Антье Маргрет Венгнер
Герхард Зимайстер
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48578942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201600014A1 publication Critical patent/EA201600014A1/ru
Publication of EA028800B1 publication Critical patent/EA028800B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к комбинации, содержащей ингибитор киназы Mps-1 и митотический ингибитор. Настоящее изобретение также относится к применению указанной комбинации для лечения рака, в частности рака поджелудочной железы, глиобластомы, рака яичников, немелкоклеточной карциномы легких, рака молочной железы и/или рака желудочно-кишечного тракта.
EA201600014A 2013-06-13 2014-06-11 Комбинация производного имидазопиридазина и митотического средства для лечения рака EA028800B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13171818 2013-06-13
EP13171818.1 2013-06-13
PCT/EP2014/062133 WO2014198776A1 (en) 2013-06-13 2014-06-11 Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer

Publications (2)

Publication Number Publication Date
EA201600014A1 true EA201600014A1 (ru) 2016-06-30
EA028800B1 EA028800B1 (ru) 2017-12-29

Family

ID=48578942

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600014A EA028800B1 (ru) 2013-06-13 2014-06-11 Комбинация производного имидазопиридазина и митотического средства для лечения рака

Country Status (17)

Country Link
US (1) US20160175306A1 (ru)
EP (1) EP3007698A1 (ru)
JP (1) JP2016521740A (ru)
KR (1) KR20160018749A (ru)
CN (1) CN105392484A (ru)
AP (1) AP2015008915A0 (ru)
AU (1) AU2014280224A1 (ru)
CA (1) CA2914995A1 (ru)
CL (1) CL2015003606A1 (ru)
EA (1) EA028800B1 (ru)
HK (1) HK1222341A1 (ru)
MA (1) MA38657A1 (ru)
MX (1) MX2015017245A (ru)
PH (1) PH12015502756A1 (ru)
SG (1) SG11201510034QA (ru)
TN (1) TN2015000544A1 (ru)
WO (1) WO2014198776A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP6166289B2 (ja) * 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
WO2014020041A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□

Also Published As

Publication number Publication date
SG11201510034QA (en) 2016-01-28
TN2015000544A1 (en) 2017-04-06
AU2014280224A1 (en) 2016-01-07
EP3007698A1 (en) 2016-04-20
CA2914995A1 (en) 2014-12-18
EA028800B1 (ru) 2017-12-29
CN105392484A (zh) 2016-03-09
HK1222341A1 (zh) 2017-06-30
MX2015017245A (es) 2016-07-20
PH12015502756A1 (en) 2016-03-14
JP2016521740A (ja) 2016-07-25
MA38657A1 (fr) 2018-05-31
AP2015008915A0 (en) 2015-12-31
US20160175306A1 (en) 2016-06-23
CL2015003606A1 (es) 2016-08-12
KR20160018749A (ko) 2016-02-17
WO2014198776A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
NZ724691A (en) Quinoline derivatives as smo inhibitors
HK1216853A1 (zh) 治療胰腺癌的方法
TN2015000396A1 (en) Antibody drug conjugates
DK3030255T3 (da) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201591509A1 (ru) Ингибиторы cdc7
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
EA201590962A1 (ru) Новые соединения
IN2014DN05885A (ru)
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
NZ627480A (en) Inhibitors of iap
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
HK1211322A1 (en) Methods of treating pancreatic cancer
WO2014113407A3 (en) Use of small molecule inhibitors targeting eya tyrosine phosphatase
MX2015013021A (es) 5-bromo-indirrubinas.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
EA201600014A1 (ru) Комбинация производного имидазопиридазина и митотического средства для лечения рака
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
EA201791264A1 (ru) Соединения для лечения злокачественного новообразования
TR201401768A2 (tr) Miyasteninin tedavisine yönelik bir kompozisyon.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU